9/27/2022  9:10:42 AM Chg. -0.200 Volume Bid9:11:55 AM Ask9:11:55 AM Market Capitalization Dividend Y. P/E Ratio
37.950CHF -0.52% 602
Turnover: 22,892.850
37.900Bid Size: 172 38.200Ask Size: 46 454.82 mill.CHF 0.00% -

Business description

Basilea Pharmaceutica AG, founded in 2000, is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. The company has a portfolio of marketed drugs: Zevtera®/Mabelio® (ceftobiprole) is an intravenous antibiotic from the cephalosporin class amd Cresemba® (isavuconazole) is an intravenous and oral antifungal from the azole class. Furthermore Basilea's pipeline includes three early-stage oncology drug candidates. Basilea Pharmaceutica AG is headquartered in Basel, Switzerland.
 

Management board & Supervisory board

CEO
David Veitch
Management board
Adesh Kaul, Dr. Gerrit Hauck, Dr. Laurenz Kellenberger, Dr. Marc Engelhardt
Supervisory board
Domenico Scala, Dr. Martin Nicklasson, Dr. Nicole Onetto, Dr. Thomas Werner, Ronald Scott, Steven D. Skolsky
 

Company data

Name: Basilea Pharmaceutica AG
Address: Grenzacherstraße 487,CH-4005 Basel
Phone: +41-61-606-1111
Fax: +41-61-606-1112
E-mail: info_basilea@basilea.com
Internet: www.basilea.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 75.81%
IPO date: -

Investor relations

Name: Peer Nils Schröder
IR phone: +41-61-606-1102
IR Fax: +41-61-606-1238
IR e-mail: investor_relations@basilea.com

Main Shareholders

Freefloat
 
75.81%
UBS Group AG
 
7.68%
Credit Suisse Group AG
 
7.08%
Black Creek Global Balanced Fund
 
4.91%
BlackRock, Inc
 
2.48%
Franklin Resources, Inc.
 
2.04%